5-HT2A receptor stimulation by DOI, a 5-HT2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens

Brain Research

Volumn 972, Issue 1-2, 2003, Pages 216-221

  Kuroki, Toshihide ^a   Meltzer, Herbert Y ^b   Ichikawa, Junji ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT 2A receptor; Amphetamine; Dopamine; M100907; Microdialysis; Rat; 1 (2,5 Dimethoxy 4 iodophenyl) aminopropane hydrochloride

Indexed keywords

1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMPHETAMINE; DOPAMINE; EPLIVANSERIN; SEROTONIN 1A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DOPAMINE RELEASE; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; DRUG SELECTIVITY; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

EID: 0037449148     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)02516-2     Document Type: Article

References (41)

1. 2 receptor regulation of extracellular GABA levels in the prefrontal cortex. Neuropsychopharmacology. 20:1999;92-96.
2. 2A/2C receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 27:2002;430-441.
3. 2 receptor stimulation of dopamine release in the posterior but not anterior nucleus accumbens of the rat. J. Neurochem. 75:2000;1625-1633.
4. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Nat. Acad. Sci. USA. 94:1997;2569-2574.
5. Carr D.B., O'Donnell P., Card J.P., Sesack S.R. Dopamine terminals in the rat prefrontal cortex synapse on pyramidal cells that project to the nucleus accumbens. J. Neurosci. 19:1999;11049-11060.
6. 2A receptor in the central nervous system of adult rat. J. Comp. Neurol. 409:1999;187-209.
7. 2A/2C receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J. Neurochem. 73:1999;1033-1042.
8. 2 serotonin receptors: evidence for a lack of selectivity. J. Med. Chem. 35:1992;734-740.
9. 2A receptor activation enhances dialysis levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology. 38:1999;315-317.
10. 2 receptor agonists. Eur. J. Pharmacol. 264:1994;325-330.
11. 2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum. Brain Res. 698:1995;204-208.
12. Ichikawa J., Meltzer H.Y. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur. Arch. Psychiatry Clin. Neurosci. 249:(Suppl. 4):1999;S90-S98.
13. 2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release. Brain Res. 97:2001;151-155.
14. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76:2001;1521-1531.
15. 1A receptor agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens. Eur. J. Pharmacol. 287:1995;179-184.
16. Kuczenski R., Melega W.P., Cho A.K., Segal D.S. Extracellular dopamine and amphetamine after systemic administration: comparison to the behavioral response. J. Pharmacol. Exp. Ther. 282:1997;591-596.
17. 1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex. Brain Res. 743:1996;357-361.
18. Kuroki T., Meltzer H.Y., Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288:1999;774-781.
19. 1A receptor agonist, attenuated amphetamine-induced dopamine synthesis in rat striatum, but not nucleus accumbens or medial prefrontal cortex. Brain Res. 872:2000;204-207.
20. 2A/2C receptor agonist and antagonist on phencyclidine-induced dopamine release in rat medial prefrontal cortex. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 23:1999;1259-1275.
21. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Nat. Acad. Sci. USA. 93:1996;9235-9240.
22. 2 receptors. Psychopharmacology. 112:1993;S40-S54.
23. 2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res. 947:2002;157-165.
24. 2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J. Neurochem. 74:2000;693-701.
25. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25:1999;233-255.
26. i values. J. Pharmacol. Exp. Ther. 251:1989;238-246.
27. 2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology. 37:1998;953-955.
28. Nash J.F., Meltzer H.Y., Gudelsky G.A. Effect of 3,4-methylenedioxymethamphetamine on 3,4-dihydroxyphenylalanine accumulation in the striatum and nucleus accumbens. J. Neurochem. 54:1990;1062-1067.
29. 3 mediated control of dopaminergic function. Psychopharmacology. 112:1993;S60-67.
30. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, New York.
31. Pehek E.A. Local infusion of the serotonin antagonists ritanserin or ICS205,930 increases in vivo dopamine release in the rat medial prefrontal cortex. Synapse. 24:1996;12-18.
32. Pehek E.A., Yanming B. Ritanserin administration potentiates amphetamine-stimulated dopamine release in the rat prefrontal cortex. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 21:1997;671-682.
33. 2A antagonist, attenuates dopamine release in the rat medial prefrontal cortex. Brain Res. 888:2001;51-59.
34. 2C/2B receptor subtypes respectively modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology. 26:2002;311-324.
35. 2C receptor. J. Pharmacol. Exp. Ther. 299:2001;83-89.
36. 1C receptors. J. Pharmacol. Exp. Ther. 260:1992;1361-1365.
37. 2A receptor blockade. J. Pharmacol. Exp. Ther. 277:1996;1541-1549.
38. 2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL100,907 and the amphetamine analogue, 3,4-methlenedioxymethamphetamine. Eur. J. Pharmacol. 223:1992;65-74.
39. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., Van Gompel P., Lesage A.S., et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 124:1996;57-73.
40. 2A heteroceptors on thalamocortical glutamatergic neurons. J. Neurosci. 20:2000;8846-8852.
41. 11C]raclopride. Neuropsychopharmacology. 20:1999;424-433.